A safety study done by the maker of the asthma drug omalizumab (Xolair) suggests it poses slightly increased but serious risks for heart attacks and mini-strokes known as TIAs (transient ischemic attacks), the FDA says.
from WebMD Health http://ift.tt/1vpGflo
No comments:
Post a Comment